Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World January 6, 2010 Ned Stafford	UK libel laws threaten scientific debate A libel lawsuit brought by GE Healthcare has succeeded in silencing an eminent Danish radiologist who questioned the safety of one of the firm's drugs, but the firm is now being accused by some in the scientific community of trying to stifle legitimate scientific discussion.
BusinessWeek April 14, 2011 Rachel Layne	GE and Siemens: Less May Mean More (Profits) The medical gear makers see an opportunity for their information technology units as hospitals are pressured to improve efficiency and curb waste
The Motley Fool September 8, 2008 Rich Duprey	The Coming Great Pharma Panic The FDA's drug warning list provides dangerously little information.
Pharmaceutical Executive April 1, 2006 Jill Wechsler	Washington Report: A Warning Trend Washington's new answer to drug safety concerns is more warnings and more disclosure of undigested data. But warnings can go too far. Haven't FDA's critics ever heard the story of the boy who cried wolf?
BusinessWeek October 15, 2009	Healthy Business In May, GE launched the "Healthymagination" campaign to promote its growing medical division. Here are some vital statistics.
The Motley Fool May 25, 2010 Brian Orelli	GE's Looking Healthy and Imaginative Happy 1-year birthday, Healthymagination. GE is also focused on saving itself some money through decreased health-care costs.
Pharmaceutical Executive August 1, 2012 Jill Wechsler	Fleshing Out FDASIA Medical apps, e-submissions, counterfeit drugs, and imports tucked into fairly "clean" user-fee renewal legislation. In late June leading legislators reached across party lines to quickly approve the Food and Drug Administration Safety and Innovation Act.
BusinessWeek April 26, 2004 Brady & Capell	GE Breaks The Mold To Spur Innovation Immelt is merging GE's health unit with Britain's Amersham -- and putting its chief in charge
The Motley Fool April 13, 2004 Lita Epstein	GE Bets on Health Care Closing a $9.5 billion deal for the U.K.'s Amersham assures a major role for GE Healthcare.
Pharmaceutical Executive December 1, 2013	FDA Pursues Delicate Balancing Act The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler.
Pharmaceutical Executive April 1, 2009 Patrick Clinton	Dear Commissioner... Unsolicited advice for FDA's next leader: Keep it real, fight popular delusions, and somehow, please, defend the agency.
BusinessWeek March 4, 2010 Frederik Balfour	The Ka-Ching in China Luring Medical Giants GE, Siemens, and others are angling for a piece of the $125 billion Beijing plans to spend on health care.
The Motley Fool October 10, 2005 Stephen D. Simpson	The FDA: Boon, Bane, Whipping Boy Everyone wants the FDA to be faster, better, and cheaper, but that may not be a credible expectation. Investors would do well to keep an eye on the FDA because its policies and pressures ultimately filter down to our medicine cabinets, wallets, and portfolios.
Pharmaceutical Executive June 1, 2012 Jill Wechsler	Innovation and Collaboration A rash of "pro-innovative" approaches for testing and regulating medical products offer ways to speed more new products to market.
Pharmaceutical Executive July 3, 2007 Louis A. Morris	Culture Shock The withdrawal of Vioxx signaled a sea change. Welcome to the Culture of Drug Safety. The FDA is making changes in the way it reviews drug safety. Post-marketing staff has been enlarged 25%, and new, tougher laws are on the way.
American Family Physician December 1, 2000 William M. Rados	Online Information for Health Care Professionals The home page of the U.S. Food and Drug Administration has undergone a major revision. The agency's Web site, which includes more than 100,000 documents, is now easier to search and covers the full scope of the FDA's activities...
CIO March 15, 2006 Allan Holmes	Rx for Risk As it revamps its workflow processes, the FDA is relying on technology to reduce the risk that unsafe substances will get into the market.
Pharmaceutical Executive November 1, 2011 Jill Wechsler	The Drug Shortages Struggle Clamor for critical therapies prompts probes of prices, production practices.
Pharmaceutical Executive December 1, 2006 Richard A. Epstein	FDA vs. the Individual In this excerpt from his important new book Overdose, an ever controversial legal scholar argues that the current system overvalues risk, ignores individual differences, and deprives patients of valuable treatments.
Pharmaceutical Executive September 1, 2005 Jill Wechsler	Washington Report: Crawford Steps Up As FDA's new commissioner takes the reins, his key challenge is restoring trust in the agency.
The Motley Fool September 14, 2010 Luke Timmerman	Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug.
The Motley Fool April 6, 2011 Sloan & Gerth	Setting the Record Straight on GE's Taxes There's a heated debate over General Electric's taxes in places ranging from the front page of the New York Times to the blogosphere to, of all places, "The Daily Show."
HBS Working Knowledge September 24, 2007 Sean Silverthorne	The FDA: What Will the Next 100 Years Bring? The challenge for FDA leaders is to maintain morale and focus, and to back up decisions with solid data on benefits and risks to different consumer populations.
BusinessWeek March 28, 2005 Diane Brady	The Immelt Revolution He's turning GE's culture upside down, demanding far more risk and innovation
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
BusinessWeek January 27, 2011	Obama's and GE's Strategies Are in Sync Where the priorities of the President and GE align.
The Motley Fool June 1, 2011 Katie Spence	This Stock Is Poised for Growth General Electric is moving on up.
The Motley Fool June 13, 2005 Stephen D. Simpson	GE Sparks Small Cardiology Companies A defibrillator distribution deal could boost Cardiac Science's sales. Investors who believe that this agreement could be a real catalyst might want to investigate further.
Pharmaceutical Executive January 1, 2006 Clinton & Wechsler	What Ever Happened to Critical Path FDA's ambitious program to improve drug development disappeared from view almost as soon as it was announced. Suddenly, it's back, but is it here to stay?
Pharmaceutical Executive March 1, 2012 Ron Cohen	FDA's Necessary Dose of Reality There's no fast-acting salve, but there are several steps that can be taken to streamline many of the procedures at FDA. And it begins with leadership.
The Motley Fool October 25, 2010 Rich Smith	GE: $5 Billion Down, $25 Billion to Go GE spends, but not wisely.
BusinessWeek October 13, 2003 Diane Brady	Will Jeff Immelt's New Push Pay Off for GE? The giant is gambling that helping customers beyond the call of duty will reboot growth.
Pharmaceutical Executive June 1, 2007 Clinton & Wechsler	The View From Inside Commissioner Andrew von Eschenbach on drug safety, DTC advertising, FDA's culture, and how the agency plans to bring itself into the age of molecular medicine.
The Motley Fool January 20, 2012 Tamara Rutter	GE Sends Mixed Signals A look at the conglomerate's quarterly earnings.
Pharmaceutical Executive May 1, 2005 Jill Wechsler	Washington Report: The Pendulum Swings FDA cracks down on safety. Haven't we been here before? Perhaps in the end, the public will have a better understanding of the dangers associated with all pharmaceuticals and how virtually impossible it is to guarantee a risk-free medical treatment.
The Motley Fool January 22, 2010 Alex Dumortier	Don't Buy GE Shares Before Reading This While the company expects flat growth in 2010, it's projecting "solid growth for 2011 and beyond." Should investors pick up shares before that growth begins to materialize?
Knowledge@Wharton	Bringing Good Things to GE: Now It's Jeff Immelt's Turn At General Electric Co. managers are groomed for meticulous corporate planning. But in his first months as chief executive of the world's most valuable company, Jeffrey R. Immelt has had more than his share of surprises...
Pharmaceutical Executive January 1, 2006 Kenneth I. Kaitin	Opinion: Memo to von Eschenbach FDA's acting commissioner has an opportunity to clarify a lot of misconceptions about the agency's role in regulating drug safety. His first order of business should be to explain exactly what FDA doesn't do.
The Motley Fool August 2, 2004 Tom Taulli	InVision on the Radar GE is a pro at acquisitions. And strong due diligence definitely helped it in its deal to purchase InVision.
The Motley Fool April 15, 2005 W.D. Crotty	GE's Spring Cleaning General Electric continues to downsize its insurance unit, which is a weak spot in an otherwise strong quarter.
BusinessWeek July 16, 2009 Aaron Ricadela	Google's Battle in Business Software Google is bent on taking on Microsoft, but its slow progress shows just how difficult that can be.
U.S. Banker February 2010 Kathy Brister	GE Capital Thinks Small After suffering staggering commercial real estate losses, GE s financing unit shifts its focus to small businesses.
BusinessWeek March 11, 2009 Reena Jana	Innovation Trickles in a New Direction Products traditionally are created in rich nations and repackaged for emerging ones. But General Electric, Nokia, and others are reversing the process.
The Motley Fool February 15, 2011 Rich Smith	General Electric Calls It Quits One more big energy buy and GE's done. (For now.)
The Motley Fool October 6, 2008 David Lee Smith	Let's See If GE Cuts It With the market doing daily belly rolls, GE's earnings report will be meaningful.
The Motley Fool July 13, 2007 Anders Bylund	GE Sticking to Its Guns Why change, when what you're doing works so remarkably well? GE is sticking to what it knows best, which is rebuilding and reshaping itself into whatever form can support the highest profits today. Investors, take note.
BusinessWeek February 24, 2011 Rubin & Donmoyer	GE's Tax-Break Guard Dogs The diversified conglomerate is likely to spend big bucks on lobbyists as the battle to reshape the U.S. Tax Code heats up.
The Motley Fool December 17, 2010 Rich Smith	General Electric Wants to Be a Millionaire The company's goal: to leave behind the days when GE's consumer finance business drove its growth efforts (into a ditch), and return to the company's roots as a maker of "stuff."
BusinessWeek October 13, 2003	Immelt on Being an "Embedded Partner" GE's CEO talks about his new push to use his multifaceted company's vast knowhow to help its customers grow faster and smarter.
The Motley Fool April 25, 2011 Rich Smith	General Electric: Good News, Bad Timing Things are looking up for GE -- except that stock price, that is.